At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Mar 23, 2026 at 16:01 ET
Apogee Therapeutics (APGE) has announced a $300 million public offering of common stock, with an additional $45 million option for underwriters, to fund clinical development and general corporate purposes. The offering represents significant near-term dilution and is being conducted amid recent insider selling.
- Apogee Therapeutics is conducting a $300 million public offering of common stock.
- Underwriters have a 30-day option to purchase up to an additional $45 million in shares.
- Proceeds will fund preclinical/clinical trials, manufacturing, commercial readiness, R&D, and general corporate purposes.
- Recent insider activity includes two sales totaling $642K in the past 30 days.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access